[{"orgOrder":0,"company":"CMP Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CMP Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CMP Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CMP Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"||Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Ausa Pharmed Co.,Ltd","sponsor":"Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shenzhen Ausa Pharmed Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","highestDevelopmentStatusID":"11","companyTruncated":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | "},{"orgOrder":0,"company":"Shenzhen Ausa Pharmed Co.,Ltd","sponsor":"Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Shenzhen Ausa Pharmed Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | ","highestDevelopmentStatusID":"11","companyTruncated":"Shenzhen Ausa Pharmed Co.,Ltd \/ Peking University First Hospital | Second Affiliated Hospital, Nanchang University | The First People's Hospital of Lianyungang | The Affiliated Hospital Of Guizhou Medical University | Lianyungang Oriental Hospital | Tengzhou Central People's Hospital | "},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Candesartan Cilexetil","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Apontis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Apontis Pharma \/ Midas Pharma"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Health Start Pharmaceutical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amlodipine Besylate","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Overseas Pharma \/ Health Start Pharmaceutical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Health Start Pharmaceutical Technology"},{"orgOrder":0,"company":"Burke Therapeutics","sponsor":"Coeptis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Amlodipine Besylate","moa":"||Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Burke Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Burke Therapeutics \/ Coeptis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Burke Therapeutics \/ Coeptis Pharmaceuticals"},{"orgOrder":0,"company":"George Medicines","sponsor":"Piramal Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"George Medicines \/ Piramal Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"George Medicines \/ Piramal Pharma Solutions"}]
Find Clinical Drug Pipeline Developments & Deals for EXFORGE
Details :
Widaplik is a combination tablet of telmisartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker, and indapamide, for treating hypertension.
Details :
Caduet-Generic is a combinational medicine which consists of amlodipine besylate & atorvastatin calcium. It is indicated for the treatment of high blood pressure.
Details :
Norliqva (Amlodipine) oral solution, 1 mg/mL, first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, for treatment of hypertension in patients 6 years of age and older.
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
